Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 4, 2007, Pages 284-290

  Romero, Silvia ^a   Stanton, Gail ^b   DeFelice, Joseph ^b   Schreiber, Fred ^c   Rago, Randy ^d   Fishman, Mayer ^d  

^a Florida Cancer Specialists   (United States)

^b Morton Plant Hospital   (United States)

^c Watson Clinic   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Dexamethasone; Hormone refractory prostate cancer; Thalidomide

Indexed keywords

DEXAMETHASONE; PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BILIRUBIN BLOOD LEVEL; BLEEDING; BRADYCARDIA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIPLOPIA; DIZZINESS; DRUG TOLERABILITY; EDEMA; FATIGUE; HEART ARRHYTHMIA; HOT FLUSH; HUMAN; HYPOTENSION; INSOMNIA; IRRITABILITY; LEG CRAMP; LEUKOPENIA; LUNG EMBOLISM; MALE; NEUROPATHY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY TRACT DISEASE; SENSORY NEUROPATHY; SIDE EFFECT; SKIN CANCER; SKIN CYST; SKIN INFECTION; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; URETER OBSTRUCTION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 34447096189     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.09.017     Document Type: Article

References (17)

1. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
2. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 17 (1999) 2506-2513
3. Berry W., Dakhil S., Modiano M., et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168 (2002) 2439-2443
4. Storlie J.A., Buckner J.C., Wiseman G.A., et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76 (1995) 96-100
5. Saika T., Kusaka N., Tsushima T., et al. Treatment of androgen-independent prostate cancer with dexamethasone: A prospective study in stage D2 patients. Int J Urol 8 (2001) 290-294
6. Akakura K., Suzuki H., Ueda T., et al. Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin-6. Prostate 56 (2003) 106-109
7. Kumar S., Witzig T.E., and Rajkumar S.V. Thalidomide: Current role in the treatment of non-plasma cell malignancies. J Clin Oncol 22 (2004) 2477-2488
8. Macpherson G.R., Franks M., Tomoaia-Cotisel A., et al. Current status of thalidomide and its role in the treatment of metastatic prostate cancer. Crit Rev Oncol Hematol Suppl 6 (2003) S49-S57
9. Figg W.D., Dahut W., Duray P., et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7 (2001) 1888-1893
10. Dahut W.L., Gulley J.L., Arlen P.M., et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2532-2539
11. Cox M.C., Dahut W.L., and Figg W.D. The use of thalidomide in androgen-independent prostate cancer. Urol Oncol 24 (2006) 246-249
12. Horne III M.K., Figg W.D., Arlen P., et al. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 23 (2003) 315-318
13. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
14. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
15. Matias P.M., Carrondo M.A., Coelho R., et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45 (2002) 1439-1446
16. Krishnan A.V., Zhao X.Y., Swami S., et al. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: Therapeutic implications for androgen-independent prostate cancer. Endocrinology 143 (2002) 1889-1900
17. Zhao X.Y., Malloy P.J., Krishnan A.V., et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6 (2000) 703-706